SUVEN LIFE SCIENCES LTD vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of SUVEN LIFE SCIENCES LTD (SUVEN) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads SUVEN vs TORNTPHARM on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-29.50
P/E ratio
77.50
13.30
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹-10.48
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-78.80%
Return on equity
27.40%
-77.00%
Return on capital
15.00%
-4001.00%
EBITDA margin
33.00%
-3942.86%
Net margin
15.29%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-20.63%
Revenue CAGR (3Y)
13.27%
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹10,090 Cr
Market cap
₹1.68L Cr
₹7 Cr
Revenue
₹13,980 Cr
₹-276 Cr
Net profit
₹2,138 Cr
0.01
Debt / equity
1.69
SUVEN LIFE SCIENCES LTD
  • + ["Company is almost debt free."]
  • ["Stock is trading at 16.3 times its book value", "Company has low interest coverage ratio.", "Promoter holding has decreased over last quarter: -4.68%", "The company has delivered a poor sales growth of -12.0% over past five years.", "Company has a low return on equity of -65.9% over last 3 years.", "Debtor days have increased from 63.7 to 77.5 days.", "Working capital days have increased from 55.6 days to 506 days"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
SUVEN LIFE SCIENCES LTD full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

SUVEN vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX